Strain of microorganism bacillus smithii tbm112 mscl p737 and its application as food or feed additive, or component of probiotic composition, and probiotic composition

FIELD: medicine.

SUBSTANCE: strain of microorganism Bacillus smithii TBMI12 MSCL P737 is resistant to metronidasole. Strain is applied as food or feed additive, and as component of probiotic compositions. Probiotic composition of said strain in form of endospores is applied as probiotic in order to perform antibacterial impact, colonise gastrointestinal tract and stimulate immune system, as antibacterial medication.

EFFECT: invention ensures resistance to diseases and prevention of bacterial infections with application of strain Bacillus smithii TBMI12 MSCL P737.

11 cl, 3 dwg

 

The technical FIELD TO WHICH the INVENTION RELATES.

The invention relates to the field of biotechnology and probiotic bacterial strain that can be used to prevent bacterial infections of the gastrointestinal tract of vertebrates and stimulation of their immune system.

The LEVEL of TECHNOLOGY

The idea of antagonism between bacteria and pathogens belongs to the time of Lister and Fleming. The use of living organisms to colonize the gastrointestinal tract to stimulate the immune system or antibiotic exposure is a newer idea. Oral insertion living microorganisms, having a positive impact on the body, are called probiotics (Martins, F.S. et al. (2005) Screening of yeast as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J. Gen. Appl. 25 Environ. 51:83-92). Usually they come from the genus Lactobacillus.

Unfortunately, the successful application of these lactobacilli as probiotics hampered the mass death of microorganisms under the influence of gastric acid and bile (Spinosa, M.R. et 30 al. (2002) On the fate of ingested Bacillus spores. Res. Environ. 151:361-368). However, if instead of the vegetative cells are disputes, their survival rate is much higher. At the same time, the drugs introduced in the form of spores, are not the less the effect is positive, than the drugs used in the vegetative form. More precisely, the ability to save disputes for an unlimited period of time is an advantage, and thus the application of the dispute became an alternative to the use of antibiotics in agriculture (Wolken, W.A.M. et al. 5 (2003) What can spores do for us? Trends in Biotechnology. 21:338-345). In prophylactic and therapeutic purposes are most commonly used spores of the genus Bacillus, such as Century clausii, B. subtilis, B. pumilus and B. Cereus (Duc, L.H. 10 et al. (2004) Characterization of Bacillus probiotics available for human use. Appl. Environ Environ. 70:2161-2171).

The authors of the present invention were interested in the possibility of using indoor Bacillus sp. in combination with antibiotics to fight the infection. This combination is widely used in East and South Asia, as it helps to reduce complications associated with antibiotic treatment.

Typically, the endospores are also resistant to the antibiotics. The disadvantage of this method is the distribution of genes resistantanti to antibiotics.

Closest to the present invention counterparts from the prior art based on the use of sporogenous bacteria Bacillus coagulans used as a probiotic Supplement to forage for animals (WO 93/14187, A. Adami et al., 1993), as well as on the combination of probiotic asporogenic microorganisms Bacillus subtilis and/or Bacillus clausii and the argument for IP is of use in the pharmaceutical industry, nutrition and/or food industry (EP 1405641 A2, G. Dondi, 2004). The experiments described in these publications are usually indirect: probiotic effect is investigated in in vitro experiments (EP 1107772, Farmer, Sean. Probiotic, lactic acid-producing bacteria and uses thereof 1999) or by simple measurement of positive gain in weight in animals that participated in the experiment (Adami, A., et al. (1993) A bacterial strain of the species Bacillus coagulans: its use as a probiotic agent. PCT/EP 93/0030).

DISCLOSURE of INVENTIONS

Objects of the present invention is a strain of the microorganism Bacillus smithii TBMI12 MSCL P737 and its functional equivalents (endospores, the mutants, the result of the multiplication, derivatives), as well as the use of this strain as a probiotic agent for antibacterial treatment to colonize the gastrointestinal tract and stimulate the immune system; as well as its use as a dietary Supplement and a probiotic composition.

The object of the present invention is Bacillus smithii TBMI12 MSCL P737 - was isolated from faeces of healthy adult men. The resulting strain was isolated during the description of the microbiological composition of feces, which verified the presence of thermophilic species Bacillus sp. A fresh sample of feces was ten-fold diluted with 0.9% NaCl solution and suspended.

The resulting suspension was heated for 15 minutes at a temperature of 85°C With the aim of you is the population of vegetative cells. The heated sample was cultured in the medium with the composition shown in Michelson, T.; Kask, K.; Jõgi, E.; Talpsep, E.; Suitso, I.; Nurk, A. (2006). l(+)-Lactic acid producer Bacillus coagulans SIM 7 DSM 14043 and its comparison with Lactobacillus delbrueckii ssp. lactis DSM 20073. Enzyme and Microbial Tech. A Cup with a level of inoculation with 100 μl were incubated at a temperature of 55°C for 24 hours. From the obtained colonies were doing suspension (0.2% Tween 80) in various concentrations, followed by culturing in the above environment has been cleansed pure culture of Bacillus smithii TBMI12 MSCL P737.

Culture and morphological characteristics

Colony P737 strain of Bacillus smithii TBMI12 MSCL have a straight edge, a convex surface and very viscous. The diameter colorless (without pigment) colonies is about 5 mm Gram plochodrazni bacteria are usually non-aggregated, but if stress is also generated in the circuit. Cells are mobile and form a subterminal endospores.

Physiological and biochemical characteristics

Growth of the strain Bacillus smithii TBMI12 MSCL P737 is logged on the monosaccharides, such as glucose, galactose, fructose, xylose and arabinose; disaccharides, such as sucrose, maltose and lactose; polysaccharides, such as starch. As for the type of metabolism, this strain is aerotolerance lactic acid bacteria: it ferments carbohydrates to lactic acid is without release of carbon dioxide. Due to the presence of catalase is tolerant of oxygen.

Temperature growth

Strain of Bacillus smithii TBMI12 MSCL P737 is logged when a wide range of temperatures from room temperature up to 55°C. Heating for 40 minutes at a temperature of 85°C did not cause any harm to endosperm and did not affect their development.

Recognition

Strain of Bacillus smithii TBMI12 MSCL P737 was recognized on the basis of 16S rRNA gene sequences (GenBank Accession No EF010852). Closest to him were Bacillus smithii R-71170 with 99% compliance. Bacillus smithii JCM9076 with 96% compliance and Bacillus eolicus 4-1T with 95% compliance.

With 19.10.2006 is the deposition of strain Bacillus smithii TBMI12 MSCL P737 in the Collection of microbial strains of Latvia (MSCL) number P737.

Bacillus smithii TBMI12 MSCL P737 provides an interesting opportunity: due to the type of metabolism of this strain is resistant to metronidazole. This makes possible the use of the strain Bacillus smithii TBMI12 MSCL P737 without additional markers of resistance in the treatment of infections of the gastrointestinal tract caused by Clostridium difficile, as above Clostridium difficile is sensitive to metronidazole, this antibiotic commonly used to treat such infections. Additionally in addition to this antibiotic together with a strain of Bacillus smithii TBMI12 MSCL P737 possible in principle to use other antibiotics.

The strain according to the present from which bretania is used in the following order.

Colonization of the gastrointestinal tract with the purpose of antibacterial effects.

Clostridium difficile, which is part of the normal microflora of the person, is usually harmless. However, after antibiotic treatment, which upset the balance of microflora in the gastrointestinal tract, it can cause pseudomembranous colitis. To avoid proliferation of Clostridium difficile and subsequent disease should prophylactically to colonize the gastrointestinal tract with probiotic bacteria, such as strains of Bacillus smithii TBMI12 MSCL P737, which can survive in the form of endospore with antibiotic treatment.

Colonization of the gastrointestinal tract with the purpose of providing resistance to the disease and prevention of bacterial infections.

The Salmonella infection usually occurs as a result of eating certain foods. Bacteria that are trapped in the gastrointestinal tract, are attached to the wall of the intestine, penetrate through it and blood are spread throughout the body. In the liver, the bacteria multiply and then return to the bowel, which can cause diarrhoea. Sick Pets and birds can infect humans through eggs and meat.

Despite the fact that usually this disease is not dangerous to human life (only 2% of infected people need treatment with antibiotics), more, the rationale for asno prophylactically to colonize the gastrointestinal tract of man, domestic animals and birds by a strain of Bacillus smithii TBMI12 MSCL P737, than to let them get sick.

Use to stimulate the immune system.

The keeping of animals in sanitary conditions reduces the risk of pathogenic infections. Unfortunately, this has a negative side effect: the immune system gets used to the sterile conditions, and even accidental contact with the normally non-pathogenic bacterium can cause illness.

In order to avoid this, the immune system must constantly be exposed to immunogens.

The use of indoor probiotic bacteria Bacillus smithii TBMI12 MSCL P737 helps to support the immune system in constant readiness to resist pathogens.

Use as a food additive.

Strain of Bacillus smithii TBMI12 MSCL can be used as a food additive in the form of both vegetative cells and endospore. Vegetative cells before use must be dried. Application of the strain Bacillus smithii TBMI12 MSCL in the form of endospore is preferred because it maximizes the probiotic effect, and at the same time endospores can be easily stored. Preferred is the use of endospore in the form of dry preparations. In this case, essentially no limitations on the Fort is Obrajuelo drug substance, as the cells in an inactive form, such as endospores, tolerate extreme conditions (high sugar concentration, low pH, long-term storage, preservatives).

Use as probiotic compositions.

Vegetative cells or endospores of Bacillus smithii TBMI12 MSCL can be used as a component of probiotic compositions. Forming substances are intended to simplify the production, storage and use of the drug, as well as to support the probiotic effect of Bacillus smithii TBMI12 MSCL.

External use as an antibacterial agent.

The antagonism between bacteria can be used for hygienic treatment of the outer surface of the host organism from harmful bacteria. It should be noted the fact that in contrast to chemical or physical sterilization, which indiscriminately destroys all microorganisms, the antagonism between bacteria selectively. This means that it is possible to suppress potential pathogens without destroying the normal microflora.

BRIEF DESCRIPTION of DRAWINGS

Figure 1 Number (□) Bacillus smithii TBMI12 MSCL P737 (n=5) with standard error in the faeces of hamsters (CFU/g) after treatment with antibiotics (ampicillin, 3 mg per hamster), inoculation of Clostridium difficile VPI 25 10463 (104cells) and treatment of the probiotic strain Bacillus sithii TBMI12 MSCL R (1×10 8endospore; on the 2nd, 3rd and 4th day).

Figure 2. For infectious diseases caused by Salmonella in mice. An infectious disease caused by pathogenic Salmonella Enteritidis wt mice not subjected to colonization (□) and subjected to colonization (■) endospore Bacillus smithii TBMI12 MSCL P737, was determined on samples of faeces, tissues of the liver or spleen, cultured on XLD plate in accordance with SOME indicator.

Figure 3. The median number of Clostridium difficile VPI 10463 with RMS error in the faeces of the tested animals (CFU/g). Mice receiving combined treatment metronidazole and Bacillus smithii TBMI12 MSCL P737 (108) (n=5) (□), and mice treated only metronidazole (■). The p value for 2-nd and 4-th day indicates the statistical significance of the observed differences.

The IMPLEMENTATION of the INVENTION

1. Colonization of the gastrointestinal tract with the purpose of antibacterial effects.

To demonstrate the in vivo experiment the ability of Bacillus smithii TBMI12 MSCL P737 successfully colonize the gastrointestinal tract of vertebrates as the study of animals used hamsters (Mesocritus auratus).

On the microflora of normal hamsters had a negative impact of 3 mg of ampicillin, which was administered intragastrically. After 24 hours of the investigated animals infected cells (105) strain Clostridium dificile VPI 10463. Two hours before infection part hamsters introduced endospores of Bacillus smithii TBMI12 MSCL R (108). Additionally, the same dose of bacteria was administered to the same group of hamsters after 24 and 48 hours. The hamsters that did not receive the strain of Bacillus smithii TBMI12 MSCL P737, and therefore not subjected to colonization, were killed after 48 hours, whereas the colonized hamsters survived. Colonies of Bacillus smithii TBMI12 MSCL P737 still existed in the gastrointestinal tract within one month after injection (Figure 1). The results of this experiment are particularly important, because hamsters are especially exposed to Clostridium difficile toxin, and this bacterium (Bacillus smithii TBMI12 MSCL P737) is not part of their normal flora.

With this experiment we have demonstrated that Bacillus smithii TBMI12 MSCL P737 able to colonize the gastrointestinal tract over a long period of time and thus prevent the development of hamsters infections caused by Clostridium difficile.

2. Colonization of the gastrointestinal tract with the purpose of providing resistance to the disease and prevention of bacterial infections.

To ensure the continued colonization of the gastrointestinal tract of mice (Mus musculus BALB/c) three doses (108) endospore probiotic bacteria Bacillus smithii TBMI12 MSCL P737 were intragastrically administered every 24 hours. On the third day after the last dose studies the target animals were inoculated with cells of Salmonella Enteritidis wt (10 6). After two weeks it was possible to cultivate cells of Salmonella Enteritidis from tissue samples of liver, spleen and faeces only 40% of the investigated animals. 60% of the investigated animals were not infected with Salmonella. The control group was not colonized by strain Bacillus smithii TBMI12 MSCL P737, and it was introduced only cells of Salmonella Enteritidis wt. All mice in this group were infected. The disease was significantly slowed down: in infected mice that were colonized by strain Bacillus smithii TBMI12 MSCL P737, infection was registered only on day 10 after inoculation, whereas in the faeces of non-colonized mice to distinguish cells of Salmonella Enteritidis was already on the first day after inoculation. The above experiment is illustrated in figure 2. Thanks to slower progression of the disease, you can take measures to combat the infection and alleviate the pathological state. Based on the conducted experiments, we can conclude that the use of the strain Bacillus smithii TBMI12 MSCL P737 as a probiotic agent can prevent the development of infectious diseases caused by Salmonella, and slow down the disease.

3. Use to stimulate the immune system.

With the aim of stimulating the immune system of mice with three doses (108) endospore strain of Bacillus smithii TBMI12 MSCL R was administered intragastrically rootimage 24 hours. Four hours after the last dose of investigational animals were infected cells of Salmonella Enteritidis wt (106). Thanks to an earlier stimulation of the immune system of the studied animals were not infected with Salmonella. For the first time it was possible to detect cells of Salmonella Enteritidis only on day 10 after inoculation and in the faeces only 10% of the investigated animals. In General, the Salmonella infection occurred in only 40% of the investigated animals colonized by endospore Bacillus smithii TBMI12 MSCL P737. The immune system of the animals of the control group was not exposed to stimulating endospore strain of Bacillus smithii TBMI12 MSCL P737, and it was introduced only cells of Salmonella Enteritidis wt. (106). 100% of these mice were infected. The disease also increased: in the faeces of non-colonized mice to distinguish cells of Salmonella Enteritidis was already on the first day after inoculation.

Accordingly, the repeated introduction of endospore probiotic bacteria strain Bacillus smithii TBMI12 MSCL P737 effectively stimulates the immune system to provide protection against infections caused by Salmonella.

4. Use as food and/or feed additives. Mice and hamsters fed endospore Bacillus smithii TBMI12 MSCL P737 in different doses and observed their effects on animals. The result of the experiment was not observed any negative effects. At the same itself is time positive impact was evident: it was possible to restore the balance of microflora in experimental animals, which was disrupted as a result of antibiotic treatment, and the studied animals were significantly more resistant to bacterial infections of the gastrointestinal tract, as endospores of Bacillus smithii TBMI12 MSCL P737 pre stimulated their immune system.

Accordingly, the probiotic bacteria strain Bacillus smithii TBMI12 MSCL P737 suitable for use as food and/or feed additives.

5. Use as a component of probiotic compositions.

With the purpose of introducing endospore Bacillus smithii TBMI12 MSCL P737 mice and hamsters prepared probiotic composition of endospore Bacillus smithii TBMI12 MSCL P737 and water, deionized during reverse osmosis. In 1 ml of probiotic compositions contained from 106up to 1010endospore. This greatly simplified the storage and the introduction of endospore.

With the introduction of the composition containing the strain Bacillus smithii TBMI12 MSCL P737, increased resistance of the investigated animals to bacterial infections of the gastrointestinal tract. Accordingly, the probiotic bacteria strain Bacillus smithii TBMI12 MSCL P737 suitable for use as a component of probiotic compositions.

6. External use as an antibacterial agent.

To demonstrate antibiosis between Bacillus smithii TBMI12 MSCL P737 and other bacteria, experiments were carried out in vitro. At first the m experiment, cells of Bacillus smithii TBMI12 MSCL P737 were grown in cups PDA (Fluka) at a temperature of 55°C and then radially around them cultivated different types of bacteria. In the experiment used Bacillus cereus, Aeromonas hydrophila, Erwinia carotovora, Pseudomonas fluorescens, Serratia marcesens, Enterobacter aerogenes, Escherichia coli, Micrococcus luteus, Skaphylococcus aureus, Proteus vulgaris, Salmonella Typhimurium and Salmonella Enteritidis. Then the cups were incubated at 30°C. At 75% of the species of bacteria used in the experiment, we observed suppression of growth near the colony of Bacillus smithii TBMI12 MSCL P737. It should be noted that among the used species of bacteria were several pathogens, such as Salmonella Enteritidis, Salmonella Typhimurium, Staphylococcus aureus. At the same time, an increase of 25% of the bacteria was not suppressed Bacillus smithii TBMI12 MSCL P737, including species that make up the normal flora, such as Escherichia coli.

Accordingly, between Bacillus smithii TBMI12 MSCL P737 and other bacteria is antibiosis, allowing externally applied Bacillus smithii TBMI12 MSCL P737 antibacterial purposes.

7. The use of a probiotic composition in combination with antibiotics.

To demonstrate positive interaction between endospore Bacillus smithii TBMI12 MSCL P737 and antibiotics, the authors conducted an experiment in vivo with mice (BALB/c).

Before infection toxic strain of Clostridum difficile VPI 10643 mice should be 5-day treatment cefoxitin in order to weaken their microflora. After inoculation with strain Clostridum difficile VPI 10643 mice were divided into two groups. The first group of mice was injected metronidazole for treatment of Clostridium difficile (through 24 after inoculation, 15 mg/kg), the second group was administered metronidazole in combination with endospore Bacillus smithii TBMI12 MSCL R (108endospore on each dose of antibiotic (15 µg/kg)).

Experiment has shown that if mice received combined treatment (metronidazole + Bacillus smithii TBMI12 MSCL R), the number of Clostridium difficile in feces decreased more than 10 times (Figure 3). Thus, the introduction of endospore Bacillus smithii TBMI12 MSCL R has potential applications in the treatment of antibiotic.

Applications of the present invention is not limited to the described examples; there may be other embodiments of the invention.

1. The strain of microorganism Bacillus smithii TBMI12 MSCL P737 exhibiting resistance to metronidazole.

2. Application of the strain of microorganism Bacillus smithii TBMI12 MSCL P737 according to claim 1 as a food or feed Supplement.

3. Application of the strain of microorganism Bacillus smithii TBMI12 MSCL R according to claim 1 as a component of probiotic compositions.

4. Probiotic composition comprising 106-1010indoor strain of the microorganism Bacillus smithii TBMI12 MSCL P737 according to claim 1 in 1 ml of water.

5. The composition according to claim 4, further containing one or more antibiotics.

6. The composition according to claim 5, whereby the said antibiotic is metronidazole.

7. The composition according to claim 4 for use as probiotics to colonize the gastrointestinal tract.

8. Composicao claim 4 for use as a probiotic for the prevention of bacterial infections of the gastrointestinal tract.

9. The composition according to claim 4 for use as a probiotic to stimulate the immune system.

10. The composition according to claim 4 for external use as an antibacterial agent.

11. The composition according to claim 4 for use as a medical means to reduce or eliminate adverse effects during treatment with antibiotics.



 

Same patents:

FIELD: food industry.

SUBSTANCE: method envisages preparation of an initial suspension represented by a bacterial starter for production of cheese or cultured milk products. The produced initial suspension is placed into a vacuum drier and dried in a mode of pressure modification from atmospheric level to a vacuum amount no less than 4.5 mm Hg during the first quarter of the whole drying process.

EFFECT: invention allows to enhance quality of the end product and reduce the period of its drying.

2 tbl, 2 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: group of inventions relates to biotechnology and a Cupriavidus eutrophus VKPM B-10646 bacteria strain which produces polyhydroxy alkanoates (PHA) and a method of producing said strain. The strain is isolated from Ralstonia eutropha VKPM B-8562 during long multi-step selection based on effectiveness of synthesis of multicomponent PHA. PHA is obtained by culturing the strain in conditions of aeration and mixing on a liquid salt medium with limited nitrogen. The medium contains a growing substrate with an additional carbon source. The growing substrate used is glucose or fructose or 3-butyric acid or a gaseous mixture - hydrogen, oxygen and carbon dioxide, or synthetic gas mixed with oxygen. The additional carbon source used is a solution of potassium 3-valarate or solution of potassium 3-valerate and potassium 3-hexanoate, or solution of potassium 3-valerate, potassium 3-hexanoate and acrylate, or solution of potassium 3-valerate, or solution of potassium 3-hexanoate and acrylate, or solution of 3-butyric acid and 4-butyrolactone, or solution of 3-butyric acid, 4- butyrolactone and potassium 3-valerate, or solution of 3-butyric acid, 4- butyrolactone and potassium 3-hexanoate, or solution of 3-butyric acid, 4- butyrolactone, potassium 3-valerate and potassium 3-hexanoate.

EFFECT: invention enables to obtain polyhydroxy alkanoate producer with high output.

2 cl, 1 tbl, 15 ex

FIELD: medicine.

SUBSTANCE: synthetic nutrient medium for growing microorganisms contains citric acid, asparagine, potassium phosphate twice substituted, zinc sulfate, magnesium sulfate, iron sulfate, sodium chloride, sodium phosphate twice-substituted, glycine, succinic acid, distilled water and if necessary agar with specified component ratio.

EFFECT: invention makes it possible to increase nutritional properties of synthetic nutrient media.

2 cl, 1 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: method involves preliminary selection of concentration of a disinfectant solution at which bacteria exhibit partial sensitivity to said disinfectant. The bacteria are exposed to the disinfectant solution at the given concentration. Grown colonies of bacteria are collected after exposure to said disinfectant and then sown on a solid culture medium, followed by culturing at 37°C. Bacteria colonies isolated from those grown at the previous step are selected in amount of 1-299 colony-forming units (CFU/ml). The collected isolated colonies are resown on a culture medium and grown at conditions needed for growth of bacteria of that type, followed by dividing the grown colonies into two parts. One part of the grown bacteria colonies is exposed to the disinfectant at the selected concentration, and the other part is exposed to the disinfectant at bactericidal concentration. If upon exposure to the disinfectant at bactericidal concentration, there is no growth of bacteria or their growth ranges from 1 to 299 (CFU/ml), then the cycle of selecting bacteria grown at the previous step, their resowing on the culture medium, growing colonies of said bacteria at conditions needed for growth of said type of bacteria and exposing the grown colonies to the disinfectant at the selected and bactericidal concentrations is repeated once more until after exposing the column to the disinfectant solution at bactericidal concentration, growth of bacteria on the culture medium is equal to 300 (CFU/ml), which indicates bacterial resistance to the disinfectant.

EFFECT: invention enables to simulate bacterial resistance to a disinfectant, evaluate build-up of resistance and bactericidal potential of hospital strains to disinfectants during their practical use.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method provides test inoculation of a nutrient medium containing pancreatic fish flour hydolyzate, fermentative meat peptone, NaCl, Tween-80, CaCl2, sodium thiosulphate (Na2S2O3 × 5H2O), ferrous ammonium sulphate ((NH4)2SO4 × FeSO4 × 6H2O), sorbite, bromthymol blue, irgasan (DP-300), rifampicin, NaOH, agar and distilled water in the preset proportions. Pancreatic fish flour hydolyzate, peptone, NaCl, agar are dissolved with heating, sterilised at 121°C for 20 min and thereafter added in a hot medium of the other components specified above. The inoculations are incubated on the nutrient medium in aerobic conditions at temperature 37°C and/or 28°C for 24-48 h and assessed by the presence of black-centre green or dark grey colonies surrounded by a cloudy precipitate zone in the nutrient medium.

EFFECT: invention allows simplifying and providing higher specificity of Shewanella bacteria recovery and identification.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, and concerns a lactic bacteria Lactobacillus reuteri DSM 17938 strain stimulating IL-10 production and hence CD4+CD25+TR-cell proliferation used for making a probiotic product. The probiotic product contains Lactobacillus reuteri DSM 17938 strain and additionally medium-chain triglyceride oil.

EFFECT: use of the probiotic product promoted a favorable effect on intestinal colic in a newborn baby.

3 cl, 3 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: inoculate contains in a mixture or in a combination, main L-cystein of formula HSCH2CH(NH2)CO2H and at least one B.animalis lactis strain. Said cysteine and at least one B.animalis lactis strain are contained or have the form of at least one frozen granule and/or at least one lyophilizate. The pH value of the solution produced by thawing of at least one granule and/or dissolution, of at least one lyophilizate in the relation making 1 to 2 g of the lyophilizate per 8-10 ml of H2O, makes at least 4. L-cysteine contains in the inoculate in an amount within 1 g per 1·1014 CFU to 1 g per 3.5·1010 CFU, of at least one B.animalis lactis strain or all used B.animalis lactis strains whereas the same are numerous. Using the offered inoculate provides stimulation of B.animalis lactis growth and/or metabolism on a lactic substratum to produce a fermented diary product.

EFFECT: high probiotic value of the product.

21 cl, 9 dwg, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: nutrient medium contains yeast water, beef hydrolyzate, sodium chloride, glucose, glycerin, sodium citrate, sodium metabisulphite and distilled water.

EFFECT: invention allows providing optimum conditions for brucellous microbe growth, replication in a transport nutrient medium at any distances.

3 ex

FIELD: medicine.

SUBSTANCE: strain of bacteria Bacillus thuringiensis BIOS-1 VKPM B-10709, possessing insectoacaricidal activity against representatives of leaf-eating and sucking pests, such as representatives of orders Lepidoptera, Coleoptera, Homoptera, Thysanoptera and Acariformes, doing harm to crops, is deposited in All-Russian collection of industrial microorganisms (VKPM), Federal State Unitary Enterprise GosNIIgenetika under number B-10709.

EFFECT: invention makes it possible to increase mortality of representatives of leaf-eating and sucking pests, doing harm to crops.

6 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: strain of Bifidobacterium longum is separated from bowels content of healthy baby and is deposited in Government collection of microorganisms of normal microflora (GKNM) FSIS "MNIIEM named after G.N. Gabrichevskiy Rospotrebnadzor " under registration number 230. Strain multiplies in various nutrition mediua with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: Bifidobacterium longum strain has acid-forming activity, antagonistic activity with respect to pathogenic and opportunistic microorganisms, ferments milk, which makes it possible to apply it for obtaining bifidocontaining production.

2 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and can be applied in treatment of vertical squint with hyperfunction of inferior oblique eye muscle. For this purpose temporally in area of lower-internal angle of orbit near the place of inferior oblique eye muscle attachment transcutaneous injections of medication of botulinic toxin A in dose 20 UN are made. Preliminarily medication is diluted in 1.5 ml of physiological solution of sodium chloride. Then, immediately after this introduction rehabilitative conservative treatment is performed until eye-moving function is restored.

EFFECT: in case of refusal from surgery method creates conditions of maximal patient's plasticity to perception of typical conservative treatment of said type of squint, which leads to restoration of sight in shorter terms, prevention of disease recurrence.

1 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, and concerns a lactic bacteria Lactobacillus reuteri DSM 17938 strain stimulating IL-10 production and hence CD4+CD25+TR-cell proliferation used for making a probiotic product. The probiotic product contains Lactobacillus reuteri DSM 17938 strain and additionally medium-chain triglyceride oil.

EFFECT: use of the probiotic product promoted a favorable effect on intestinal colic in a newborn baby.

3 cl, 3 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine, namely to allergology, and can be used for prevention of development of respiratory allergies in a subject. That is ensured by introduction of an effective amount of Lactobacillus rhamnosus GG (LGG) either in a pregnant mother's body, and/or postnatal in a feeding mother's body, or in a subject directly.

EFFECT: introduction of LGG allows preventing an early allergic sensitisation and the following development of respiratory allergies due to higher production of serum antibodies IgA in a subject, and also prevention of allergic inflammation in lungs and respiratory ways.

12 cl, 13 ex, 9 dwg

FIELD: food industry.

SUBSTANCE: for prebiotic preparation one uses Lactobacillus acidophilus EP 317/402 strains with concentration in the final product no less than 1×108 - 4×108 CFU/ml. One prepares a mixture of D3 vitamin and hydrogenised nut oil heated to 40-50°C, taken at a ratio of 1:10 (vol). Then the said composition is mixed with fresh defatted milk heated to 40-50°C at a ration of 2:98 and proceeds with homogenisation. The milk, thus prepared, is chilled to a temperature of 37-38°C; Lactobacillus acidophilus EP 317/402 lactobacteriae starter is added to it, taken in an amount of 0.10%-0.12% of the prepared milk volume, as well as a mixture of calcium and magnesium minerals in a quantity (per 1 l of the mixture) equal to 40% of the adult or child organism daily demand for such minerals. The calcium and magnesium minerals mixture accounts for 0.056%-0.060% of the liquid component weight while the ration of calcium to magnesium minerals quantity qual to 2.5:1. The produced mixture is thoroughly stirred and maintained at a temperature of 37-38°C during 12-15 h. Co-presence of lactobacteriae and calcium in the product has a positive effect on calcium assimilation and gut microflora stabilisation while presence of EP 317/402 strain acidophilic lactobacteriae enhances immune response, having a positive effect on bowel performance, improves metabolic processes in the organism.

EFFECT: increase of prebiotic efficiency of the produced fermented milk drinking product and enhancement osteoporosis prevention effect which renders the product suitable for consumption by a wide range of consumers of all ages.

3 cl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to children's uro-andrology. Preliminary ultrasonic examination is carried out. Presence of orchopathy is detected by size of gonads and presence of reflux into racemose plexuses and in case of its presence surgery of varicocele is performed. At the first stage into complex therapy included are antimicrobial therapy in combination with antifungal drugs, probiotics, uroseptics and immunomodulators, complex of vitamins with microelements, including zinc and selenium, prostatotropic phytotherapy in form of per oral medications and rectal suppositories. Enzymes wobenzime or phlogenzym and vein-tonics are administered, which are introduced successively - first detralex, after it aescusan, angioprotectors. Medications possessing antihypoxic, antioxidant and membrane-stabilising action - actovegin, vitamin E, ascorutin, cytochrome C - are applied. At the background of pharmacological therapy magnetic therapy is administered to patient rectally. At the second stage ultrasonic examination is performed, parameters of arterial hemodynamics are determined at the level of intratesticular recurrent arteries - index of peripheral resistance and pulsation index, in case of increase or reduction of which antispasmodic medications are administered. In addition, introduction of vein-tonics - escusan and troxevasin, prostatotropic medications, vitamins in complex with microelements, enzymes is continued.

EFFECT: method makes it possible to prevent secondary complications, reduction of fertility and infertility, increase in future life quality of active part of male population, improving demographic indices.

3 cl, 1 ex

FIELD: medicine.

SUBSTANCE: strain of Bifidobacterium longum is separated from bowels content of healthy baby and is deposited in Government collection of microorganisms of normal microflora (GKNM) FSIS "MNIIEM named after G.N. Gabrichevskiy Rospotrebnadzor " under registration number 230. Strain multiplies in various nutrition mediua with accumulation of production biomass with high concentration of bifidobacteria.

EFFECT: Bifidobacterium longum strain has acid-forming activity, antagonistic activity with respect to pathogenic and opportunistic microorganisms, ferments milk, which makes it possible to apply it for obtaining bifidocontaining production.

2 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: in invention described is composition for causing immune reaction against Neisseria meningitidis basing on vesicles, separated from bacteria N. meningitidis, in which endogenous gen GNA 1870 is inactivated and which is transformed by gene construction, coding polypeptide GNA 1870. Such bacterium insures super-expression of GNA 1870 polypeptide in vesicles of N. meningitidis. Composition can additionally contain antigen vesicle from second, third bacteria of N. meningitidis, on condition that both bacteria are genetically different from each other and from said first bacteria. GNA 1870 polypeptides, expressed by first, second and third bacteria are also genetically different from each other. Invention describes method of exciting immune reaction against bacteria of species Neisseria by introduction to mammal of composition based on vesicles, containing polypeptide GNA 1870, as well as method of obtaining composition based on vesicles, obtained as a result of culturing in proper way prepared bacteria, by their mixing with pharmaceutically acceptable carrier.

EFFECT: invention provides protective immunity against broad spectrum of N meningitidis strains, including strains N meningitidis of serogroup B.

45 cl, 20 dwg, 5 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to method of obtaining medication, which possesses gastroprotective action (versions). Method of obtaining medication, possessing gastroprotective action, according to which in milk after autoclaving and cooling added are 2% of activated liquid culture of Bifidobacterium longum D 379 M, dry water-soluble extract of liquorice Glycyrrhiza Glabra L. root and natural zeolite - clinoptilolite, mixture is carefully mixed and thermostated until clot formation with specified acidity. Method of obtaining medication, possessing gastroprotective action, according to which in milk after autoclaving and cooling added are 2% of activated liquid culture of Bifidobacterium longum D 379 M, dry water-soluble extract of liquorice Glycyrrhiza Glabra L. root and natural zeolite - clinoptilolite, mixture is carefully mixed and thermostated until formation of clot with specified acidity.

EFFECT: medication, obtained by upper claimed method (versions) positively influences functional condition of gastrointestinal tract, effectively influences various links of pathological process, normalises malfunctions of microbiogenesis of intestine.

2 cl, 4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: according to the invention, versions of an immunobiological antiallergic agent contain Lactobacillus acidophilus 100 "аш" PA strain, collection No. 207, is stored in the State collection of microorganisms of normal microflora Federal State Research Institution Gabrichevskiy Moscow Research Institution of Epidemiology and Microbiology of Federal Service for Supervision of Consumer Rights and Human Welfare in a culture medium in amount 106-1010 CFU/ml. The immunobiological antiallergic agent additionally contains species-specific virulent bacteriophages and bacteriophages with induced virulence, a biomass of Lactobacillus acidophilus "КзШз4" strain in a culture medium in amount 106-1010 CFU/ml, a biomass of Lactobacillus acidophilus NKi strain in the culture medium in amount 106-1010 CFU/ml and a biomass of Bifidobacterium bacteria in the culture medium in amount 106-1010 CFU/ml. The immunobiological antiallergic agent additionally contains target additives in amount 0.01-95.0 wt % from mass of the agent. The additives are selected from a number of: glycine, cysteine, copper sulphate, copper gluconate, quinosol, chitosan, licorice root extract, hips extract, origanum extract, cranberry extract and a flavouring agent. The immunobiological antiallergic agent is presented in the form of a suspension. The Lactobacillus acidophilus 100 "аш" PA strain is produced by means of a sequence of multiple passages through a nutrient medium MPC with added sources of histamine, Cu1+, Cu2+, Co2+, Ni2+ ions and at culture pH 6.2-7.4. The agent is used for prevention and treatment of allergic or pseudo-allergic disease without an accompanying pathology or in a combination with an infectious disease, intestinal dysbacteriosis and psychological adaptation disorders.

EFFECT: more efficient antiallergic action of the immunobiological agent on the basis of lactobacilli.

10 cl, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to drugs and concerns a composition for intestinal dysbacteriosis correction, characterised by the fact that it is prepared on the basis of a consortium of lactobacilli strains providing a ratio of total short-chain monocarboxylic fatty acids of fractions (C2-C4) and a butyric acid isomer as 20:1 to 40:1.

EFFECT: composition under the invention provides personification of intestinal dysbacteriosis correction in the patients with a higher value of an invert correlation of total short-chain monocarboxylic fatty acids (C4-C6) to total fractions of their isomers (C4-C6) in faeces.

3 ex

FIELD: biotechnology, microbiology, medicine.

SUBSTANCE: invention relates to the strain Lactobacillus paracasei CNCM I-2116 used for diarrhea prophylaxis causing by pathogenic microorganisms. Supernatant of this strain culture elicits ability to prevent colonization of intestine with pathogenic microorganisms causing diarrhea also and this strain is designated for preparing agent used for prophylaxis and/or treatment of disorders associated with diarrhea. Agent for oral administration represents therapeutically effective dose of the strain L. paracasei CNCM I-2116 or supernatant of its culture and acceptable foodstuff. Invention provides the enhanced viability of the strain in its applying and effectiveness in prophylaxis of adhesion to intestine cells and invasion to intestine cells of pathogenic microorganisms causing diarrhea.

EFFECT: valuable medicinal properties of strain.

5 cl, 8 dwg, 10 ex

Up!